Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + Cemiplimab vs Relatlimab + Nivolumab in Advanced Melanoma
NCT06246916Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Countries
- 2
01
Overview
A Phase 3 trial of fianlimab in melanoma, sponsored by Regeneron Pharmaceuticals. Started Sep 2024; status: recruiting.
02
Drugs
fianlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06246916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246916.